Cell Biotech Co. Ltd (049960) — Cash Flow Quality Index
Cell Biotech Co. Ltd (049960) has a Cash Flow Quality Index of 1.20x as of September 2025. Operating cash flow of ₩4.15 Billion exceeds net income of ₩3.45 Billion, indicating high earnings quality where cash backs reported profits. Explore long-term investment intensity of Cell Biotech Co. Ltd to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cell Biotech Co. Ltd Cash Flow Quality Index (2011–2024)
Historical Cash Flow Quality Index for Cell Biotech Co. Ltd across 14 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Cell Biotech Co. Ltd (049960) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Cell Biotech Co. Ltd (2011–2024)
Year-by-year earnings quality comparison for Cell Biotech Co. Ltd. For live market cap and the full company financial profile, see 049960 stock market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.27x | ₩19.27 Billion | ₩15.13 Billion | ▲ +2.7% |
| 2023 | 1.24x | ₩7.82 Billion | ₩6.30 Billion | ▼ -19.9% |
| 2022 | 1.55x | ₩12.81 Billion | ₩8.28 Billion | ▲ +7.9% |
| 2021 | 1.43x | ₩14.89 Billion | ₩10.38 Billion | ▼ -52.2% |
| 2020 | 3.00x | ₩9.56 Billion | ₩3.19 Billion | ▲ +112.0% |
| 2019 | 1.41x | ₩10.23 Billion | ₩7.23 Billion | ▲ +96.2% |
| 2018 | 0.72x | ₩13.98 Billion | ₩19.38 Billion | ▼ -41.8% |
| 2017 | 1.24x | ₩22.53 Billion | ₩18.20 Billion | ▲ +27.2% |
| 2016 | 0.97x | ₩17.99 Billion | ₩18.48 Billion | ▼ -6.8% |
| 2015 | 1.04x | ₩18.24 Billion | ₩17.46 Billion | ▲ +9.7% |
| 2014 | 0.95x | ₩9.91 Billion | ₩10.40 Billion | ▼ -17.4% |
| 2013 | 1.15x | ₩8.99 Billion | ₩7.80 Billion | ▲ +14.7% |
| 2012 | 1.00x | ₩6.17 Billion | ₩6.14 Billion | ▼ -4.2% |
| 2011 | 1.05x | ₩5.45 Billion | ₩5.20 Billion | — |